154 related articles for article (PubMed ID: 37712717)
61. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
[TBL] [Abstract][Full Text] [Related]
62. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
[TBL] [Abstract][Full Text] [Related]
63. Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies.
Bauml J; Mick R; Zhang Y; Watt CD; Vachani A; Aggarwal C; Evans T; Langer C
Clin Lung Cancer; 2013 Sep; 14(5):581-91. PubMed ID: 23827517
[TBL] [Abstract][Full Text] [Related]
64. Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study.
Mordant P; Brosseau S; Milleron B; Santelmo N; Fraboulet-Moreau S; Besse B; Langlais A; Gossot D; Thomas PA; Pujol JL; Ricordel C; Madelaine J; Lamy R; Audigier-Valette C; Missy P; Blons H; Barlesi F; Westeel V;
Clin Lung Cancer; 2023 Jan; 24(1):1-10. PubMed ID: 36180314
[TBL] [Abstract][Full Text] [Related]
65. Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K-ras mutation.
Kaseda K; Asakura K; Kazama A; Ozawa Y
Thorac Cancer; 2017 May; 8(3):229-237. PubMed ID: 28322512
[TBL] [Abstract][Full Text] [Related]
66. Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy.
Hondelink LM; Ernst SM; Atmodimedjo P; Cohen D; Wolf JL; Dingemans AC; Dubbink HJ; von der Thüsen JH
Eur J Cancer; 2023 Mar; 181():53-61. PubMed ID: 36638752
[TBL] [Abstract][Full Text] [Related]
67. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.
Harada H; Miyamoto K; Yamashita Y; Taniyama K; Mihara K; Nishimura M; Okada M
Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761
[TBL] [Abstract][Full Text] [Related]
68. Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
Saw SPL; Zhou S; Chen J; Lai G; Ang MK; Chua K; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Lim DWT; Tan A; Fong KW; Takano A; Cheng XM; Lim KH; Koh T; Ong BH; Tan EH; Toh CK; Skanderup AJ; Tan SH; Tan DSW
JAMA Netw Open; 2021 Nov; 4(11):e2131892. PubMed ID: 34739062
[TBL] [Abstract][Full Text] [Related]
69. Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma.
Ito M; Miyata Y; Kushitani K; Ueda D; Takeshima Y; Okada M
BMC Cancer; 2023 Mar; 23(1):248. PubMed ID: 36918771
[TBL] [Abstract][Full Text] [Related]
70. Prognostic effect of coexisting TP53 and ZFHX3 mutations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Zhang L; Zhang T; Shang B; Li Y; Cao Z; Wang H
Scand J Immunol; 2021 Sep; 94(3):e13087. PubMed ID: 35226388
[TBL] [Abstract][Full Text] [Related]
71. Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.
Renaud S; Falcoz PE; Schaëffer M; Guenot D; Romain B; Olland A; Reeb J; Santelmo N; Chenard MP; Legrain M; Voegeli AC; Beau-Faller M; Massard G
Br J Cancer; 2015 Oct; 113(8):1206-15. PubMed ID: 26372703
[TBL] [Abstract][Full Text] [Related]
72. Effect of epidermal growth factor receptor mutation on early-stage non-small cell lung cancer according to the 8th TNM classification.
Isaka T; Ito H; Nakayama H; Yokose T; Yamada K; Masuda M
Lung Cancer; 2020 Jul; 145():111-118. PubMed ID: 32428800
[TBL] [Abstract][Full Text] [Related]
73. Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing
Imai H; Onozato R; Ginnan M; Kobayashi D; Kaira K; Minato K
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34069436
[No Abstract] [Full Text] [Related]
74. Molecular assessment of lymph nodes in patients with resected stage I non-small cell lung cancer: preliminary results of a prospective study.
Ahrendt SA; Yang SC; Wu L; Roig CM; Russell P; Westra WH; Jen J; Brock MV; Heitmiller RF; Sidransky D
J Thorac Cardiovasc Surg; 2002 Mar; 123(3):466-73; discussion 473-4. PubMed ID: 11882817
[TBL] [Abstract][Full Text] [Related]
75. Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.
Sun JM; Hwang DW; Ahn JS; Ahn MJ; Park K
PLoS One; 2013; 8(5):e64816. PubMed ID: 23724098
[TBL] [Abstract][Full Text] [Related]
76. Clinicopathology and genetic profile of synchronous multiple small adenocarcinomas: implication for surgical treatment of an uncommon lung malignancy.
Lin MW; Wu CT; Kuo SW; Chang YL; Yang PC
Ann Surg Oncol; 2014 Aug; 21(8):2555-62. PubMed ID: 24643899
[TBL] [Abstract][Full Text] [Related]
77. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
Wang L; Hu H; Pan Y; Wang R; Li Y; Shen L; Yu Y; Li H; Cai D; Sun Y; Chen H
PLoS One; 2014; 9(2):e88291. PubMed ID: 24533074
[TBL] [Abstract][Full Text] [Related]
78. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
[TBL] [Abstract][Full Text] [Related]
79. Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer.
Chevallier M; Tsantoulis P; Addeo A; Friedlaender A
Cancer Genomics Proteomics; 2020; 17(5):597-603. PubMed ID: 32859638
[TBL] [Abstract][Full Text] [Related]
80. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]